T细胞在胃癌免疫联合化疗预后中的研究进展
Research Progress of T Cells in Prognosis of Gastric Cancer by Immunotherapy Combined with Chemotherapy
DOI: 10.12677/acm.2024.1451627, PDF,   
作者: 王雅静*, 刘彩霞#：内蒙古医科大学附属医院肿瘤内科，内蒙古 呼和浩特
关键词: 胃癌；T细胞；免疫联合化疗；Gastric Cancer； T Cells； Immunotherapy Combined with Chemotherapy
摘要: 胃癌是我国最常见的恶性肿瘤之一。免疫结合化疗的治疗方法在对晚期胃癌的临床研究中取得了更好的疗效，但仍有很多患者无法从中获益，存在免疫耐受现象及发生严重的免疫相关不良反应。如何在晚期胃癌患者中，选择免疫联合化疗的优势人群是临床上亟需解决的问题。T淋巴细胞是目前胃癌预后的潜在预测标志物。其与胃癌的发生、发展及预后关系目前已成为研究热点。本文就免疫联合化疗下胃癌的预后与T淋巴细胞亚群关系的研究进展进行综述。
Abstract: Stomach cancer is one of the most common malignant tumors in our country. Immunotherapy combined with chemotherapy has achieved better efficacy in clinical studies on advanced gastric cancer, but there are still many patients who cannot benefit from it, and there are immune tolerance phenomena and serious immune-related adverse reactions. How to select the dominant group of immune combined chemotherapy in advanced gastric cancer patients is an urgent problem to be solved clinically. T lymphocytes are potential prognostic markers of gastric cancer. Its relationship with the occurrence, development and prognosis of gastric cancer has become a research hotspot. In this review, the relationship between the prognosis of gastric cancer and T lymphocyte subsets under immunotherapy combined with chemotherapy was reviewed.
文章引用：王雅静, 刘彩霞. T细胞在胃癌免疫联合化疗预后中的研究进展[J]. 临床医学进展, 2024, 14(5): 1859-1864. https://doi.org/10.12677/acm.2024.1451627

参考文献

[1] Spolverato, G. and Pawlik, T.M. (2019) Clinicopathological Evaluation of Recurrence in Early Gastric Cancer. American Journal of Surgery, 157, 202-207. [Google Scholar] [CrossRef] 
[2] Kim, H.S., Kim, J.H., Kim, J.W., et al. (2016) Chemotherapy in Elderly Patients with Gastric Cancer. Journal of Cancer, 7, 88-94. [Google Scholar] [CrossRef] [PubMed]
[3] Song, Z.Y., Wu, Y.Y., Yang, J.B., et al. (2017) Progress in the Treatment of Advanced Gastric Cancer. Tumor Biology, 39, 1-7. [Google Scholar] [CrossRef] [PubMed]
[4] Soo, R.A., Chen, Z., Yan Teng, R.S., et al. (2018) Prognostic Significance of Immune Cells in Non-Small Cell Lung Cancer: Meta-Analysis. Oncotarget, 9, 24801-24820. [Google Scholar] [CrossRef] [PubMed]
[5] 何亚运, 罗泊涛, 陆元志. 肿瘤微环境中免疫抑制性细胞和细胞因子在抗肿瘤免疫反应中的作用研究进展[J]. 山东医药, 2019, 59(6): 88-92.
[6] Ghansah, T., Vohra, N., Kinney, K., et al. (2013) Dendritic Cell Immunotherapy Combined with Gemcitabine Chemotherapy Enhances Survival in a Murine Model of Pancreatic Carcinoma. Cancer Immunology, Immunotherapy, 62, 1083-1091. [Google Scholar] [CrossRef] [PubMed]
[7] Bang, Y.J., Kang, Y.K., Catenacci, D.V., et al. (2019) Pembrolizumab Alone or in Combination with Chemotherapy as First-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: Results from the Phase II Nonrandomized KEYNOTE-059 Study. Gastric Cancer, 22, 828-837. [Google Scholar] [CrossRef] [PubMed]
[8] Shitara, K., van Cutsem, E., Bang, Y.J., et al. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6, 1571-1580. [Google Scholar] [CrossRef] [PubMed]
[9] Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet, 398, 27-40. [Google Scholar] [CrossRef] 
[10] Min, H.K., Kim, J.K., Lee, S.Y., et al. (2016) Rebamipide Prevents Peripheral Arthritis and Intestinal Inflammation by Reciprocally Regulating Th17/Treg Cell Imbalance in Mice with Curdlan-Induced Spondyloarthritis. Journal of Translational Medicine, 14, Article No. 190. [Google Scholar] [CrossRef] [PubMed]
[11] 马可, 张喜平. 胃癌病人外周血及肿瘤组织调节性T细胞的表达水平及临床意义[J]. 内蒙古医科大学学报, 2017, 39(5): 422-425, 430.
[12] 王展梅, 曹芳丽, 曲琳莉, 等. 外周血T淋巴细胞亚群检测在胃癌病情监测及预后评价中的意义[J]. 癌症进展, 2016, 14(4): 369-371, 374.
[13] Li, W.W., Jiao, J., Wang, Z.Y., Wei, Y.N. and Zhang, Y.F. (2021) Clinical Efficacy of Immunotherapy Combined with Chemotherapy in Patients with Advanced Gastric Cancer, Its Effect on Nutritional Status and Changes of Peripheral Blood T Lymphocyte Subsets. Pakistan Journal of Medical Sciences, 37, 1902-1907. [Google Scholar] [CrossRef] [PubMed]
[14] 陈宝胜, 张吉水, 马秋桐. 卡瑞利珠单抗联合化疗方案对晚期胃癌患者免疫功能的影响[J]. 饮食保健, 2021(38): 15-16.
[15] Lu, X., Yang, L., Yao, D., et al. (2017) Tumor Antigen-Specific CD8 T Cells Are Negatively Regulated by Pd-1 and Tim-3 in Human Gastric Cancer. Cellular Immunology, 313, 43-51. [Google Scholar] [CrossRef] [PubMed]
[16] Thompson, E.D., Zahurak, M., Murphy, A., et al. (2017) Patterns of PD-L1 Expression and CD8 T Cell Infiltration in Gastric Adenocarcinomas and Associated Immune Stroma. Gut, 66, 794-801. [Google Scholar] [CrossRef] [PubMed]
[17] 赵鸿鹰. 胃癌患者免疫治疗联合化疗的临床效果分析[J]. 医药前沿, 2022, 12(15): 61-63.
[18] Wang, B., Zhang, Z., Liu, W. and Tan, B. (2023) Targeting Regulatory T Cells in Gastric Cancer: Pathogenesis, Immunotherapy, and Prognosis. Biomed Pharmacother, 158, 114180. [Google Scholar] [CrossRef] [PubMed]
[19] Shen, Z., Zhou, S., Wang, Y., Li, R.L., Zhong, C., Liang, C. and Sun, Y. (2010) Higher Intratumoral Infiltrated Foxp3 Treg Numbers and Foxp3 /CD8 Ratio Are Associated with Adverse Prognosis in Resectable Gastric Cancer. Journal of Cancer Research and Clinical Oncology, 136, 1585-1595. [Google Scholar] [CrossRef] [PubMed]

为你推荐